Equities research analysts expect Aetna Inc. (NYSE:AET) to announce $14.89 billion in sales for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Aetna’s earnings, with the lowest sales estimate coming in at $14.30 billion and the highest estimate coming in at $15.53 billion. Aetna posted sales of $15.73 billion in the same quarter last year, which suggests a negative year over year growth rate of 5.3%. The company is scheduled to issue its next quarterly earnings report on Tuesday, January 30th.
According to Zacks, analysts expect that Aetna will report full-year sales of $14.89 billion for the current fiscal year, with estimates ranging from $59.52 billion to $61.74 billion. For the next financial year, analysts anticipate that the business will report sales of $60.65 billion per share, with estimates ranging from $57.53 billion to $64.64 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that cover Aetna.
Aetna (NYSE:AET) last issued its quarterly earnings data on Tuesday, October 31st. The company reported $2.45 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.39. The company had revenue of $14.99 billion for the quarter, compared to analyst estimates of $15.12 billion. Aetna had a net margin of 2.93% and a return on equity of 21.84%. Aetna’s revenue was down 5.0% compared to the same quarter last year. During the same period last year, the company posted $2.07 earnings per share.
Aetna (AET) opened at $176.46 on Monday. The stock has a market cap of $57,543.61, a P/E ratio of 17.28, a P/E/G ratio of 1.61 and a beta of 0.61. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.53 and a current ratio of 0.53. Aetna has a 1-year low of $116.04 and a 1-year high of $184.98.
In other news, President Karen S. Lynch sold 15,271 shares of Aetna stock in a transaction on Monday, September 18th. The shares were sold at an average price of $161.91, for a total transaction of $2,472,527.61. Following the completion of the sale, the president now directly owns 64,261 shares in the company, valued at $10,404,498.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Margaret M. Mccarthy sold 10,288 shares of Aetna stock in a transaction on Friday, September 15th. The stock was sold at an average price of $162.85, for a total transaction of $1,675,400.80. Following the sale, the executive vice president now owns 33,563 shares of the company’s stock, valued at $5,465,734.55. The disclosure for this sale can be found here. Insiders own 0.90% of the company’s stock.
Several large investors have recently bought and sold shares of AET. Lloyds Banking Group plc acquired a new position in Aetna during the third quarter valued at $106,000. Bruderman Asset Management LLC acquired a new position in Aetna during the second quarter valued at $106,000. Moisand Fitzgerald Tamayo LLC acquired a new position in Aetna during the third quarter valued at $116,000. Westside Investment Management Inc. lifted its position in Aetna by 53.5% during the second quarter. Westside Investment Management Inc. now owns 1,148 shares of the company’s stock valued at $177,000 after purchasing an additional 400 shares during the period. Finally, Phocas Financial Corp. acquired a new position in Aetna during the second quarter valued at $182,000. Institutional investors and hedge funds own 88.41% of the company’s stock.
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related companies with MarketBeat.com's FREE daily email newsletter.